Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 17 peer-reviewed journal articles Updated
Endocrinology

Mapping Your Treatment: High Risk vs. Very High Risk

At a Glance

Osteoporosis treatment is tailored to your fracture risk. High-risk patients typically start with bone-protecting medications, while very high-risk patients begin with bone-building anabolic drugs. This anabolic-first strategy is followed by protectors to lock in bone gains.

In the past, osteoporosis treatment often followed a “one-size-fits-all” approach. Today, medical guidelines, specifically those from the American Association of Clinical Endocrinologists (AACE), use a strategy called risk stratification [1][2]. This means your treatment plan is tailored to exactly how likely you are to experience a fracture in the near future.

Before starting any pharmacological treatment, it is absolutely essential to ensure adequate intake of Calcium and Vitamin D. These minerals are the raw materials your body needs to build bone. Attempting to force bone building without these prerequisites can lead to severe hypocalcemia (dangerously low blood calcium levels) and limit the effectiveness of the treatment [3][4].

High Risk vs. Very High Risk

Your doctor will look at your T-scores, your history of fractures, and your FRAX score to place you into one of two categories:

  • High Risk: This generally includes patients with a T-score of -2.5 or lower, or those who have had a fracture in the past but not recently. For this group, treatment often begins with antiresorptive medications (like bisphosphonates or denosumab) that act as “bone protectors” to slow down bone loss [1].
  • Very High Risk: This category is for patients who need more urgent and intensive protection. You may be considered “Very High Risk” if you have:
    • A T-score below -3.0 [5][6].
    • A fracture within the last 12 months [5].
    • Multiple fractures while already on osteoporosis therapy.
    • A very high FRAX score (such as a 10-year major fracture risk over 30%) [5].

The “Anabolic-First” Strategy

For patients at Very High Risk, current guidelines strongly recommend starting with anabolic agents [1][7]. These are “bone-building” medications—such as romosozumab, teriparatide, or abaloparatide—that work by stimulating your body’s “construction crew” to actively rebuild new bone [8][9].

Starting with a bone-builder is often more effective than starting with a bone-protector because it rapidly increases bone mineral density, restores the microarchitecture, and “rebuilds the skeletal foundation” before you transition to long-term maintenance [10][11].

The Importance of Sequential Therapy

Osteoporosis treatment is rarely a single step; it is a sequential therapy plan. This concept is critical because the order of medications matters:

  1. Build It: You start with an anabolic agent (usually for 12 to 24 months) to maximize your bone gains [9][12].
  2. Lock It In: You must immediately follow the bone-builder with an antiresorptive agent (like denosumab or a bisphosphonate) [1][13].

Why the sequence is vital: If you stop an anabolic medication without starting a “protector” immediately afterward, the body will begin to break down the newly formed bone, and your bone density gains can be lost quickly [14][15]. Furthermore, starting with a protector first and then trying to switch to a builder can sometimes “blunt” the builder’s effectiveness, making it harder to gain bone later [16][17]. Your medical team will coordinate this sequence to ensure the bone you build is preserved for the long term.

Common questions in this guide

How do I know if I am high risk or very high risk for osteoporosis?
You are generally considered high risk if you have a T-score of -2.5 or lower. You may be considered very high risk if your T-score is below -3.0, you had a bone fracture in the last 12 months, or you have a very high FRAX score.
Why do doctors prescribe a bone-building medication first?
For very high-risk patients, starting with a bone-builder rapidly increases bone density and restores bone architecture. This is known as the anabolic-first strategy, and it provides a stronger skeletal foundation before moving to long-term maintenance.
What is sequential therapy for osteoporosis?
Sequential therapy is a multi-step treatment plan where the order of medications matters. It usually involves starting with an anabolic medication to build new bone, immediately followed by an antiresorptive medication to lock in those bone gains.
What happens if I stop taking my bone-building medication?
If you stop an anabolic medication without immediately starting a bone-protecting drug, your body will quickly begin to break down the newly formed bone. This causes you to rapidly lose the bone density you just worked hard to build.
Why do I need calcium and vitamin D before starting osteoporosis medication?
Calcium and vitamin D provide the essential raw materials your body needs to build new bone. Starting bone-building medications without adequate levels of these nutrients can limit the treatment's success and cause dangerously low blood calcium levels.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on the AACE 2020 guidelines, do I fall into the 'High Risk' or 'Very High Risk' category?
  2. 2.If I am 'Very High Risk,' why is starting with a bone-building medication better for me than starting with a bone-protector?
  3. 3.What is the long-term 'sequential plan' for my treatment? Which medication will I transition to after the bone-builder?
  4. 4.If I start a bone-building medication, what happens to my bone density if I have to stop it or miss a dose?
  5. 5.Are there any cardiovascular concerns that would make romosozumab a less ideal choice for me?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (17)
  1. 1

    Patterns of Teriparatide and Sequential Antiresorptive Agent Treatment Among Elderly Female Medicare Beneficiaries.

    Liu J, Laster A, Xu X, et al.

    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2021; (36(12)):2309-2316 doi:10.1002/jbmr.4439.

    PMID: 34490946
  2. 2

    AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS-2020 UPDATE.

    Camacho PM, Petak SM, Binkley N, et al.

    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2020; (26(Suppl 1)):1-46 doi:10.4158/GL-2020-0524SUPPL.

    PMID: 32427503
  3. 3

    Parathyroid carcinoma as an overlooked etiology of osteoporosis in postmenopausal women: a case report.

    Su J, Lei S, Jin M, et al.

    Frontiers in endocrinology 2025; (16()):1652919 doi:10.3389/fendo.2025.1652919.

    PMID: 41659338
  4. 4

    Proceedings of the 2016 Santa Fe Bone Symposium: New Concepts in the Management of Osteoporosis and Metabolic Bone Diseases.

    Lewiecki EM, Bilezikian JP, Bukata SV, et al.

    Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry 2017; (20(2)):134-152 doi:10.1016/j.jocd.2017.01.001.

    PMID: 28185765
  5. 5

    Romosozumab Efficacy in Postmenopausal Women With No Prior Fracture Who Fulfill Criteria for Very High Fracture Risk.

    McClung MR, Betah D, Deignan C, et al.

    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2023; (29(9)):716-722 doi:10.1016/j.eprac.2023.06.011.

    PMID: 37406858
  6. 6

    Osteoporosis: A Review.

    Morin SN, Leslie WD, Schousboe JT

    JAMA 2025; (334(10)):894-907 doi:10.1001/jama.2025.6003.

    PMID: 40587168
  7. 7

    The role of osteoanabolic agents in the management of patients with osteoporosis.

    McClung MR, Rothman MS, Lewiecki EM, et al.

    Postgraduate medicine 2022; (134(6)):541-551 doi:10.1080/00325481.2022.2069582.

    PMID: 35635798
  8. 8

    Romosozumab for the treatment of osteoporosis - a systematic review.

    Mäkinen VN, Sølling AS, McClung M, Langdahl BL

    Journal of endocrinological investigation 2025; (48(3)):547-572 doi:10.1007/s40618-024-02469-1.

    PMID: 39487940
  9. 9

    New Frontiers in Osteoporosis Therapy.

    Cheng C, Wentworth K, Shoback DM

    Annual review of medicine 2020; (71()):277-288 doi:10.1146/annurev-med-052218-020620.

    PMID: 31509477
  10. 10

    FRAME Study: The Foundation Effect of Building Bone With 1 Year of Romosozumab Leads to Continued Lower Fracture Risk After Transition to Denosumab.

    Cosman F, Crittenden DB, Ferrari S, et al.

    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2018; (33(7)):1219-1226 doi:10.1002/jbmr.3427.

    PMID: 29573473
  11. 11

    Treating osteoporosis to prevent fractures: current concepts and future developments.

    Lorentzon M

    Journal of internal medicine 2019; (285(4)):381-394 doi:10.1111/joim.12873.

    PMID: 30657216
  12. 12

    Teriparatide for osteoporosis: importance of the full course.

    Lindsay R, Krege JH, Marin F, et al.

    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2016; (27(8)):2395-410 doi:10.1007/s00198-016-3534-6.

    PMID: 26902094
  13. 13

    A systematic review of cost‑effectiveness analyses of sequential treatment for osteoporosis.

    Yu G, Tong S, Liu J, et al.

    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2023; (34(4)):641-658 doi:10.1007/s00198-022-06626-1.

    PMID: 36527476
  14. 14

    Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: The Denosumab and Teriparatide Follow-up study (DATA-Follow-up).

    Leder BZ, Tsai JN, Jiang LA, Lee H

    Bone 2017; (98()):54-58 doi:10.1016/j.bone.2017.03.006.

    PMID: 28286299
  15. 15

    Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group Study.

    McClung MR, Brown JP, Diez-Perez A, et al.

    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2018; (33(8)):1397-1406 doi:10.1002/jbmr.3452.

    PMID: 29694685
  16. 16

    Impact of the duration of previous osteoporosis treatment on the effect of romosozumab in patients with postmenopausal osteoporosis.

    Ebina K, Etani Y, Tsuboi H, et al.

    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2022; (33(11)):2441-2443 doi:10.1007/s00198-022-06545-1.

    PMID: 36066579
  17. 17

    Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures.

    Kanis JA, Harvey NC, McCloskey E, et al.

    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2020; (31(1)):1-12 doi:10.1007/s00198-019-05176-3.

    PMID: 31720707

This page explains osteoporosis risk stratification and sequential treatment strategies for educational purposes only. Always consult your endocrinologist or primary care doctor to determine the safest and most effective treatment sequence for your specific risk level.

Get notified when new evidence is published on osteoporosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.